secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001140361-24-033242
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M
--------------------------------------------------------------------------------

- Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
- GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.
- FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.
- Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.
- Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/0001140361-24-033242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/ef20032488_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-033242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer